TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17651479
Drug: Conventional quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional quadruple therapy (QT) - omeprazole 20 mg bid, bismuth citrate 120 mg qid, tetracycline 500 mg qid, metronidazole 500 mg tid for 7 days
Study: 17651479
Drug: Rifabutin-based triple
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin-based triple therapy (OAR) - omeprazole 20 mg bid, amoxicillin 1 gr bid, rifabutin 150 mg bid for 7 days
Study: 17651479
Drug: Conventional quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional quadruple therapy (QT)
Study: 17651479
Drug: Rifabutin-based triple
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin-based triple therapy (OAR)
Study: 16093415
Drug: Pairwise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pairwise therapy
Study: 10442360
Drug: UFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT plus oral calcium folinate
Study: 7844595
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular ASNase (25,000 IU/m2) weekly (n = 8)
Study: 7844595
Drug: Standard-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intramuscular ASNase (10,000 IU/m2) every 3 days (n = 12)
Study: 367433
Drug: Topical pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pindolol
Study: 367433
Drug: Intravenous pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pindolol
Study: 22745245
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg daily for 12 weeks
Study: 26303187
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive therapy (CDT) including Vodder II Manual Lymph Drainage
Study: 8964113
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin C (2 g) and vitamin E (100 and 800 U)
Study: 1803141
Drug: Endonasal calcitrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endonasal calcitrin (3 units twice a day for 1-1.5 months)
Study: 1803141
Drug: Intramuscular calcitrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular calcitrin (not specified)
Study: 6438672
Drug: Diazepam (10-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10-160 mg)
Study: 6438672
Drug: Oxazepam (30-480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (30-480 mg)
Study: 6438672
Drug: Diazepam (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (160 mg)
Study: 29322164
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.1 mg/d) plus intermittent micronized progesterone (200 mg/d for 12 days every 3 months)
Study: 29322164
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol plus intermittent micronized progesterone (TE+IMP)
Study: 22103635
Drug: BCM (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCM (50mg butalbital, 325mg acetaminophen, 40mg caffeine)
Study: 20017668
Drug: Pharmacogenomic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic therapy
Study: 20017668
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of pharmacogenomic therapy into practice
Study: 17577005
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (8 trials, 4876 participants)
Study: 17577005
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (12 trials, 12,963 participants)
Study: 17577005
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (general)
Study: 30987577
Drug: Postoperative urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative urinary NGAL at 48 hours >156ng/mL
Study: 30987577
Drug: Additive EuroSCORE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additive EuroSCORE, age, current smoking, and post-operative antibiotics usage
Study: 23998375
Drug: rhBMP-2/ACS (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP-2/ACS (1.5 mg/ml)
Study: 20082245
Drug: Combined Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Chinese drugs (Shengmai Injection by intravenous dripping and Gujin Granule by oral intake) plus Navelbine and Cisplatin (NP) chemotherapy
Study: 20082245
Drug: Navelbine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navelbine and Cisplatin (NP) chemotherapy alone
Study: 20082245
Drug: Combined Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Chinese drugs (Shengmai Injection and Gujin Granule) plus NP chemotherapy
Study: 9385493
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/d (30 patients with 37 lesions)
Study: 9385493
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg/d (40 patients with 45 lesions)
Study: 2688781
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pimozide and lithium
Study: 57914
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of gamma globulin
Study: 57914
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of gamma globulin
Study: 30790529
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid capsules
Study: 9709932
Drug: D‐AG (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐AG (500 mg daily)
Study: 9709932
Drug: DL‐AG (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐AG (1000 mg daily)
Study: 2228629
Drug: Special Intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special Intervention (SI) for preventive therapy patients
Study: 369921
Drug: Ciclazindol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclazindol (50 mg b.d.)
Study: 369921
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg b.d.)
Study: 11249050
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cisplatin 100 mg/m2 on day 1 and vinorelbine 30 mg/m2 on days 1, 8, 15, 22, with cycles repeated every four weeks (arm A)
Study: 11249050
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cisplatin and vinorelbine plus early WBRT 30 Gy/10 fx/12 days (arm B)
Study: 24760002
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate vaccine (PCV7) followed by 23-valent polysaccharide vaccine (23vPPV) 6 months later
Study: 24760002
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (23vPPV) alone
Study: 22528535
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment on day 0, 1, and 2 (Group III)
Study: 22528535
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment on days 0 and 1 (Group II)
Study: 22528535
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment on day 0 (Group I)
Study: 22528535
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment (all groups)
Study: 17885008
Drug: Isoflavone-rich soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-rich soy protein isolate (SPI+) (107 mg isoflavones/d)
Study: 17885008
Drug: Alcohol-washed soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-washed soy protein isolate (SPI-) (<6 mg isoflavones/d)
Study: 9465848
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg once daily, increased to 10 mg if necessary)
Study: 2118272
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy for 4 months
Study: 365123
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (Methylphenidate, Dextroamphetamine, Caffeine)
Study: 25937024
Drug: 12-week non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week non-surgical treatment program (individualized progressed neuromuscular exercise, patient education, insoles, dietary advice, prescription of pain medication if indicated)
Study: 25937024
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (two leaflets with information and advice on knee OA and recommended treatments)
Study: 8732377
Drug: Tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tissue plasminogen activator with intravenous heparin
Study: 8732377
Drug: Streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase plus tissue plasminogen activator with intravenous heparin
Study: 2008949
Drug: Midazolam (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1, 2, or 3 mg)
Study: 2008949
Drug: Midazolam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (3 mg)
Study: 26383577
Drug: Dental health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental health instruction before treatment
Study: 10685653
Drug: Concurrent biochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent biochemotherapy with cisplatin, vinblastine, and dacarbazine (CVD) plus IL-2 and IFN-alpha
Study: 7512679
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution without antihistamines
Study: 7512679
Drug: Haemaccel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haemaccel without antihistamines
Study: 7512679
Drug: Antihistamines (dimetindene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines (dimetindene plus cimetidine)
Study: 3343463
Drug: Sequential pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pulse defibrillation with four small mesh electrodes (6 cm2)
Study: 3343463
Drug: Sequential pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pulse defibrillation with two small (6 cm2) and two large (13 cm2) mesh electrodes
Study: 3343463
Drug: Sequential pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pulse defibrillation with four large mesh electrodes (13 cm2)
Study: 25802309
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine administered to vaccine-naive children
Study: 23810742
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) meloxicam (0.2mg/kg)
Study: 23810742
Drug: Rectal insufflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal insufflation of ozone (10 mL of 30 μg/mL)
Study: 23810742
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of ozone (0.5 mL of 30 μg/mL)
Study: 18385498
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream, applied twice weekly for 16 weeks
Study: 18385498
Drug: Placebo, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice weekly for 16 weeks
Study: 18385498
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream and Placebo
Study: 16369855
Drug: Pre-emptive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive antibiotic treatment with ceftriaxone
Study: 10211086
Drug: CAF (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (400 mg/m2 cyclophosphamide, 25 mg/m2 doxorubicin, 500 mg/m2 5-fluorouracil)
Study: 10211086
Drug: CMF (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (40 mg/m2 methotrexate, cyclophosphamide, 5-fluorouracil)
Study: 8775024
Drug: No treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment, some types of mobilization and ice, amitriptyline (as control for tension-type headaches)
Study: 2169216
Drug: Standard heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin, 5000 units subcutaneously three times a day
Study: 2169216
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin 3500 anti-Xa units subcutaneously once daily
Study: 28370327
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL of 2% lidocaine with 1:80,000 epinephrine
Study: 28370327
Drug: 0.6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL of 2% lidocaine with 1:80,000 epinephrine
Study: 27678425
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (IT) with lovastatin (40 mg/d), niacin (2.5 g/d), and colestipol (20 g/d) from 1989 to 2004, followed by double therapy with simvastatin (40–80 mg/d) and niacin from 2005 to 2006 and triple therapy of ezetimibe 10 mg and simvastatin 40 to 80 mg/d plus niacin during 2007 to 2012
Study: 22066583
Drug: Δ9-tetrahydrocannabinol (THC)
Normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Δ9-tetrahydrocannabinol (THC) inhalation
Study: 717750
Drug: Enflurane inhalation
Normalized name: enflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enflurane inhalation anaesthesia
Study: 29316908
Drug: Curamin® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curamin® (500 mg capsules containing 350 mg curcuminoids and 150 mg boswellic acid)
Study: 29316908
Drug: CuraMed® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CuraMed® (500 mg capsules containing 333 mg curcuminoids)
Study: 23770843
Drug: Fish oil‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil‐based intravenous fat emulsion (FIFE) at 1 g/kg/d
Study: 23770843
Drug: Soybean oil‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil‐based intravenous fat emulsion (SIFE)
Study: 18608562
Drug: Fibruline Instant
Normalized name: Advanced Eye Relief Redness Instant Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibruline Instant (20 g/day)
Study: 10630693
Drug: Steroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (methylprednisolone 1 g i.v. for three consecutive days at months 1, 3 and 5, plus oral prednisone 0.5 mg/kg every other day for six months) plus azathioprine 1.5 mg/kg/day for six months
Study: 10630693
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone with the same schedule
Study: 9110940
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only (control)
Study: 380910
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amineptine daily for 6 weeks
Study: 380910
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg maprotiline daily for 6 weeks
Study: 31773582
Drug: Glucocorticoid (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (GC) replacement therapy
Study: 31773582
Drug: Tailoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailoring of GC therapy
Study: 31773582
Drug: General GC
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General GC replacement therapies
Study: 27023419
Drug: Local acute
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local acute pain (capsaicin cream) (experiment 2)
Study: 25123196
Drug: Caffeine exercise
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine exercise trial (EX+CAF, 2 × 3 mg/kg of caffeine 90 min before and 30 min after exercise)
Study: 15028100
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus radical prostatectomy (study 1)
Study: 15028100
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (leuprorelin acetate with or without chlormadinone acetate, study 2)
Study: 7661936
Drug: Standardised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised treatment consisting of 18 sessions in vivo exposure and response prevention
Study: 22543884
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with carboplatin and etoposide, and concurrent chest irradiation (34 SCLC patients)
Study: 22543884
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with cisplatin and gemcitabine, and radiotherapy (49 NSCLC patients)
Study: 22543884
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time of radiotherapy
Study: 22543884
Drug: Mean oesophageal
Normalized name: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean oesophageal dose
Study: 20495585
Drug: Epidural methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural methylprednisolone (60 mg)
Study: 20495585
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam (2 mg) with epidural methylprednisolone (60 mg)
Study: 18554738
Drug: Camembert cheese
Normalized name: Penicillium camemberti
DrugBank: Penicillium camemberti (DB10809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camembert cheese (2x40 g/day for 4 weeks)
Study: 15801934
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the morning
Study: 15801934
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the evening
Study: 8445464
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical paste
Study: 3720307
Drug: Epinephrine plus
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine plus cortisol (5 mg/m2 . min) plus glucagon (3 mg/kg . min)
Study: 31727306
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (CBT) for 9 weeks (n=25)
Study: 27577862
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT)
Study: 27577862
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) sessions (optional)
Study: 21480005
Drug: Ortho All‐Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho All‐Flex diaphragm and Replens(®) lubricant gel
Study: 21480005
Drug: Replens(®) lubricant
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replens(®) lubricant gel
Study: 18648230
Drug: Propofol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (n = 6, 0.9 microg/ml target concentration)
Study: 18648230
Drug: Thiopental at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental at sedative doses (n = 6, 3 microg/ml)
Study: 17472024
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose perindopril 2 mg and indapamide 0.625 mg combination daily for 6 weeks
Study: 17472024
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose perindopril-indapamide
Study: 14583174
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 70/30
Study: 14583174
Drug: Biphasic human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic human insulin 70/30
Study: 7624734
Drug: Standard 2-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2-h oral glucose tolerance test (OGTT)
Study: 6267648
Drug: IV injection
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of 5.0 mg delta 9-THC
Study: 6267648
Drug: Smoking about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking about 13 mg delta 9-THC
Study: 6267648
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: 31772079
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg daily for 10 days
Study: 28336545
Drug: Protein- or
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein- or carbohydrate-based supplements during STRESS
Study: 28336545
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements during STRESS (control group)
Study: 21684490
Drug: Strain-Counterstrain treatment
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strain-Counterstrain treatment combined with exercise therapy